TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Tonix Pharmaceuticals Holding Corp. announced that the FDA has set a PDUFA goal date of August 15, 2025, for TNX-102 SL, which, if approved, would be the first new drug for fibromyalgia in over 15 ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration will not require an Advisory Committee meeting to discuss the ...

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia. TNX-102 SL demonstrated statistically significant ...

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

“With commercial preparations underway, we believe we are well positioned to launch TNX-102 SL for the management of fibromyalgia in the fourth quarter of this year if approved by the U.S. Food ...